Fig. 2
From: Post-symptomatic administration of hMSCs exerts therapeutic effects in SCA2 mice
Treatment with hMSCs upregulates the protein levels of neurotrophic factors in the cerebellum of SCA2 mice. A, B Western blot analysis of brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF) in the cerebellum after 24 weeks of hMSC administration (50-week-old mice). ***p < 0.001 vs. untreated WT mice; ###p < 0.001 vs. untreated SCA2 mice (two-way ANOVA with Tukey’s post-hoc analysis; n = 6 for each group). Full-length blots are presented in Supplementary Fig. 5 and Fig. 2A. C Double immunofluorescence staining was performed for calbindin and BDNF in the cerebellum of 50-week-old WT, SCA2, and SCA2 + hMSCs (MI, 1 × 105 cells)-treated mice. The scale bar represents 20 μm. A dashed line is used to differentiate between the granule cell layer and the Purkinje cell layer. D The fluorescence intensity for the quantitative co-localization of calbindin with BDNF and GDNF was measured. ***p < 0.001 vs. untreated WT mice; ###p < 0.001 vs. untreated SCA2 mice (one-way ANOVA with Tukey’s post-hoc analysis). E Double immunofluorescence staining was performed for calbindin and GDNF in the cerebellum of 50-week-old WT, SCA2, and SCA2 + hMSCs (MI, 1 × 105 cells)-treated mice. The scale bar represents 20 μm. A dashed line is used to differentiate between the granule cell layer and the Purkinje cell layer. F The fluorescence intensity for the quantitative co-localization of calbindin with GDNF was measured. ***p < 0.001 vs. untreated WT mice; ###p < 0.001 vs. untreated SCA2 mice (one-way ANOVA with Tukey’s post-hoc analysis)